EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC-ND 4.0

Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index

Laura Ross iD, Dylan Hansen, Susanna Proudman, Dinesh Khanna iD, Ariane L Herrick iD, Wendy Stevens, Murray Baron, Mandana Nikpour, Australian Scleroderma Interest Group (ASIG), Canadian Scleroderma Research Group (CSRG), the Scleroderma Clinical Trials Consortium Activity Index Working Gro…

Arthritis & Rheumatology · 2024

DOI: 10.1002/art.42939 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Laura Ross und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Melbourne and St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Severity of Illness Index, Delphi Technique. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Accurate measurement of disease activity in systemic sclerosis (SSc) remains a significant clinical challenge. The Scleroderma Clinical Trials Consortium (SCTC) convened an Activity Index (AI) Working Group (WG) to develop a novel measure of disease activity (SCTC‐AI).

Methods

Using consensus methodology, we developed a conceptual definition of disease activity. Literature review and expert consensus generated provisional SCTC‐AI items, which were reduced by Delphi survey. Provisional items were weighted against a combined endpoint of morbidity and mortality, using time‐dependent Cox proportional hazards regression analysis of the Australian Scleroderma Cohort Study (ASCS) (n = 1,254). External validation of the SCTC‐AI was performed using data collected from 1,103 Canadian Scleroderma Research Group Study participants.

Results

Disease activity in SSc was defined using consensus methodology as “aspects of disease that are reversible, or can be arrested, with time and, or effective therapy.” One‐hundred and forty‐one provisional SCTC‐AI items were generated and reduced using three rounds of Delphi survey and statistical reduction and weighting, against mortality and quality of life measures, yielding a final 24‐item index with a maximum possible score of 140. Survival analysis in an external cohort showed a graded relationship between disease activity scores and survival ( P < 0.01).

Conclusion

We present a novel instrument to quantify the burden of disease activity in SSc. We have employed a rigorous consensus‐based process in combination with data‐driven methods to develop an instrument that has face, content, and criterion validity. Further work is required to fully validate and confirm the construct and discriminative validity of the SCTC‐AI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicSeverity of Illness IndexDelphi TechniqueHumansConsensusQuality of LifeFemaleMaleMiddle AgedAustraliaReproducibility of ResultsProportional Hazards ModelsClinical Trials as Topic

Autor:innen und Institutionen

  • University of Melbourne and St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
  • St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
  • Royal Adelaide Hospital and University of Adelaide, South Australia, Australia.
  • University of Michigan, Ann Arbor.
  • The University of Manchester, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
  • Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

ORCID-Profile: Laura Ross, Dinesh Khanna, Ariane L Herrick

Zitieren

APA

Ross, L., Hansen, D., Proudman, S., Khanna, D., Herrick, A. L., Stevens, W., Baron, M., Nikpour, M., & Australian Scleroderma Interest Group (ASIG), Canadian Scleroderma Research Group (CSRG), the Scleroderma Clinical Trials Consortium Activity Index Working Gro… (2024). Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index. Arthritis & Rheumatology. https://doi.org/10.1002/art.42939

Vancouver

Ross L, Hansen D, Proudman S, Khanna D, Herrick AL, Stevens W, et al. Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index. Arthritis & Rheumatology. 2024. doi:10.1002/art.42939

BibTeX
@article{Ross2024,
  author = {Ross, Laura and Hansen, Dylan and Proudman, Susanna and Khanna, Dinesh and Herrick, Ariane L and Stevens, Wendy and Baron, Murray and Nikpour, Mandana and Australian Scleroderma Interest Group (ASIG), Canadian Scleroderma Research Group (CSRG), the Scleroderma Clinical Trials Consortium Activity Index Working Gro…, Australian Scleroderma Interest Group (ASIG), Canadian Scleroderma Research Group (CSRG), the Scleroderma Clinical Trials Consortium Activity Index Working Gro…},
  title = {Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index},
  journal = {Arthritis & Rheumatology},
  year = {2024},
  doi = {10.1002/art.42939}
}
Kostenlos starten →